Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Pediatric Rheumatology

Are Biologics Safe for JIA? Long-Term Cancer Risks

At a Glance

Extensive long-term data shows that biologics for juvenile idiopathic arthritis (JIA) are safe, and the risk of cancer is extremely low. For children with severe JIA, the dangers of untreated joint inflammation far outweigh the closely monitored risks of biologic medications.

In this answer

4 sections

01

The Cancer Warning Explained

02

What About the Risk of Infection?

03

The Real Risk: Untreated JIA

04

Biologics Have Changed the Future of JIA

Are biologics safe for long-term use? Yes. While the “black box warnings” on tumor necrosis factor (TNF) inhibitors sound alarming, large, long-term registries tracking thousands of children with JIA have consistently shown that the risk of cancer from these medications is extremely low. Modern data has not confirmed the initial fears that led to these warnings. For a child with severe JIA, the severe, well-documented dangers of untreated inflammation far outweigh the rare, closely monitored risks of biologic medications.

The Cancer Warning Explained

When biologic medications (specifically TNF inhibitors) were first introduced, a small number of rare cancers were reported, leading regulatory agencies to issue strict warnings. However, doctors now have decades of real-world data that paint a much more reassuring picture.

Large pediatric rheumatology registries tracking children on biologics have found no significant or clear-cut increased risk of malignancy compared to children treated with older medications like methotrexate [1][2][3]. Many of the rare cancers that originally caused concern were actually linked to older immune-suppressing drugs—specifically thiopurines (like azathioprine), which are often used for inflammatory bowel disease—rather than the biologics themselves [4][5][6]. When used alone or in combination with methotrexate, modern studies generally do not support an increased cancer risk from biologics in children with JIA [7][8]. Long-term follow-ups continue to show favorable safety profiles with no newly identified risks [9].

What About the Risk of Infection?

The other major component of the black box warning on TNF inhibitors is an increased risk of serious infections. Because biologics work by calming an overactive immune system, they can make it harder for your child’s body to fight off everyday bugs.

However, studies show that while on these medications, most reported infections are mild upper respiratory tract infections (like the common cold) [10][11]. When compared to children taking methotrexate, those on TNF inhibitors do not show a significantly higher risk of serious infections [12][13].

To keep your child safe, doctors use strict safety protocols:

  • Pre-treatment screening: Your child will be tested for latent (inactive) infections like tuberculosis (TB) before starting the medication [14].
  • Illness protocols: You will be given clear instructions on what to do when your child gets sick. For example, rheumatologists often recommend pausing the biologic if your child has a high fever or is taking antibiotics, resuming only after they have fully recovered.
  • Routine monitoring: Expect regular check-ups and periodic blood draws (often every few months) to monitor your child’s liver function, blood counts, and overall health.

The Real Risk: Untreated JIA

When making a treatment decision, it is critical to weigh the risks of the medication against the immediate and severe risks of untreated JIA. Uncontrolled chronic inflammation in JIA is not just painful; it causes permanent, irreversible joint damage, erosion of the bone, and loss of mobility [15][16][17].

If left untreated or under-treated, JIA can also cause serious systemic issues, including:

  • Growth Retardation: Severe inflammation can stunt a child’s normal physical growth and development [18].
  • Permanent Vision Loss: JIA can cause uveitis (inflammation of the eye), which can lead to blindness if not aggressively controlled [19][20].
  • Systemic Bone Impairment: Prolonged inflammation is associated with decreased bone density and structural bone impairment [21].

Biologics Have Changed the Future of JIA

Biologic drugs have revolutionized pediatric rheumatology by allowing many children to achieve complete remission before permanent joint damage occurs [22][23]. Studies clearly show that using these targeted medications early leads to better functional outcomes, normal growth, and a higher quality of life [24][25].

To manage any risks associated with these powerful medications, your child’s care team will partner with you for ongoing surveillance. Through baseline screenings and regular monitoring, doctors can catch any issues early, ensuring the long-term safety of your child while protecting their joints and future mobility [14].

Common questions in this guide

Do biologic medications for JIA cause cancer?
Decades of data from large pediatric registries show that the risk of cancer from biologics is extremely low. The rare cancers that originally caused concern were often linked to older immune-suppressing drugs, not the biologics themselves.
Will my child get sick more often while taking a biologic?
Because biologics calm the immune system, they can make it slightly harder to fight off everyday bugs. Most reported infections are mild upper respiratory tract infections, like the common cold, rather than serious or life-threatening illnesses.
What should I do if my child gets a fever while on a biologic?
If your child develops a high fever or requires antibiotics, your rheumatologist will typically recommend pausing the biologic medication. You will receive clear instructions on when it is safe to resume treatment after your child has fully recovered.
What kind of testing is required while my child is on a biologic?
Children on biologics need routine check-ups and periodic blood draws, usually every few months. This allows your child's care team to closely monitor their liver function, blood counts, and overall health to ensure the medication remains safe.
What happens if we choose not to treat my child's JIA?
Untreated or undertreated JIA can cause permanent, irreversible joint damage and erosion of the bone. It can also lead to stunted physical growth and severe eye inflammation called uveitis, which can cause blindness if not aggressively controlled.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my child's specific risk profile based on their age, sex, and the exact medications you are prescribing?
  2. 2.Will my child be taking a medication like methotrexate or azathioprine alongside the biologic, and how does that affect their risk profile?
  3. 3.What is your specific protocol if my child develops a high fever or needs antibiotics while on this biologic?
  4. 4.How frequently will my child need blood draws or other routine testing while on this medication?
  5. 5.Which vaccines are safe for my child to receive while taking a biologic, and which should we avoid?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Does My Child With JIA Need a 504 Plan for School?Can a Child Have JIA With Normal Blood Test Results?Can Kids with Juvenile Idiopathic Arthritis Play Sports?Is it Growing Pains or JIA? How to Tell the DifferenceDo Children Outgrow Juvenile Idiopathic Arthritis?Does Diet Help Treat Juvenile Idiopathic Arthritis?Should My Child Start Biologics Right Away for JIA?How Often Do Kids With JIA Need Uveitis Eye Exams?Is It JIA or Lyme Disease? How to Tell the DifferenceIs Juvenile Idiopathic Arthritis (JIA) Hereditary?Can Psoriatic JIA Occur Without a Rash?What Are the Emergency Signs of MAS in sJIA Children?Why Does My Child Need a TMJ MRI for JIA?Which Vaccines Are Safe for Kids on JIA Biologics?

References

References (25)
  1. 1

    Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry.

    Klein A, Becker I, Minden K, et al.

    ACR open rheumatology 2020; (2(1)):37-47 doi:10.1002/acr2.11091.

    PMID: 31943968
  2. 2

    Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.

    Armaroli G, Klein A, Ganser G, et al.

    Arthritis research & therapy 2020; (22(1)):258 doi:10.1186/s13075-020-02326-5.

    PMID: 33121528
  3. 3

    An update on the safety of biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis.

    Zimmer A, Horneff G

    Expert opinion on drug safety 2025; (24(6)):627-642 doi:10.1080/14740338.2025.2467179.

    PMID: 39946290
  4. 4

    Monitoring for Extra-Intestinal Cancers in IBD.

    Sifuentes H, Kane S

    Current gastroenterology reports 2015; (17(11)):42 doi:10.1007/s11894-015-0467-8.

    PMID: 26364836
  5. 5

    Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.

    Shah ED, Coburn ES, Nayyar A, et al.

    Alimentary pharmacology & therapeutics 2020; (51(5)):527-533 doi:10.1111/apt.15637.

    PMID: 31990422
  6. 6

    Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Review With an Emphasis on Diagnostic Differentiation From Other T-Cell/Natural Killer-Cell Neoplasms.

    Shi Y, Wang E

    Archives of pathology & laboratory medicine 2015; (139(9)):1173-80 doi:10.5858/arpa.2014-0079-RS.

    PMID: 26317456
  7. 7

    Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.

    Beukelman T, Xie F, Chen L, et al.

    Annals of the rheumatic diseases 2018; (77(7)):1012-1016 doi:10.1136/annrheumdis-2017-212613.

    PMID: 29440001
  8. 8

    Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review.

    Adrovic A, Yildiz M, Köker O, et al.

    Archives of rheumatology 2021; (36(1)):146-157 doi:10.46497/ArchRheumatol.2021.7953.

    PMID: 34046584
  9. 9

    Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry.

    Correll C, Burciu A, Bansal A, et al.

    Pediatric rheumatology online journal 2025; (23(1)):105 doi:10.1186/s12969-025-01144-w.

    PMID: 41121260
  10. 10

    Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.

    Lee WJ, Lee TA, Suda KJ, et al.

    Rheumatology (Oxford, England) 2018; (57(2)):273-282 doi:10.1093/rheumatology/kex049.

    PMID: 28431162
  11. 11

    The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis.

    Nagy A, Mátrai P, Hegyi P, et al.

    Pediatric rheumatology online journal 2019; (17(1)):4 doi:10.1186/s12969-019-0305-x.

    PMID: 30658717
  12. 12

    The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.

    Beukelman T, Xie F, Baddley JW, et al.

    Arthritis research & therapy 2016; (18(1)):210 doi:10.1186/s13075-016-1109-8.

    PMID: 27655411
  13. 13

    Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.

    Salonen PH, Salonen JH, Säilä H, et al.

    Clinical rheumatology 2020; (39(3)):853-860 doi:10.1007/s10067-019-04804-x.

    PMID: 31732822
  14. 14

    The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.

    Hernández MV, Sanmartí R, Cañete JD

    Expert opinion on drug safety 2016; (15(5)):613-24 doi:10.1517/14740338.2016.1160054.

    PMID: 26927029
  15. 15

    A possible case of juvenile idiopathic arthritis from Renaissance Lucca (Tuscany, central Italy).

    Riccomi G, Minozzi S, Aringhieri G, Giuffra V

    International journal of paleopathology 2021; (33()):72-83 doi:10.1016/j.ijpp.2021.03.002.

    PMID: 33744835
  16. 16

    Temporomandibular joint disorders as the only manifestation of juvenile idiopathic arthritis: a case report.

    Pinto JRR, Pedron IG, Utumi ER, et al.

    Einstein (Sao Paulo, Brazil) 2018; (16(3)):eRC4003 doi:10.1590/S1679-45082018RC4003.

    PMID: 30208154
  17. 17

    Bone erosions associated with systemic bone loss on HR-pQCT in women with longstanding polyarticular juvenile idiopathic arthritis.

    Ribeiro SCCR, Sales LP, Fernandes AL, et al.

    Seminars in arthritis and rheumatism 2023; (63()):152247 doi:10.1016/j.semarthrit.2023.152247.

    PMID: 37595510
  18. 18

    Risk factors for growth retardation in children with juvenile idiopathic arthritis: a case-control study.

    Zhang Y, Song L, Ma W, et al.

    BMC musculoskeletal disorders 2025; (26(1)):85 doi:10.1186/s12891-024-08247-7.

    PMID: 39871279
  19. 19

    Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report.

    Adán A, Moll-Udina A, Ramirez J, Llorenç V

    Ocular immunology and inflammation 2021; (29(1)):6-8 doi:10.1080/09273948.2019.1644350.

    PMID: 31589540
  20. 20

    Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry.

    Tarsia M, Vitale A, Gaggiano C, et al.

    Ophthalmology and therapy 2024; (13(3)):761-774 doi:10.1007/s40123-023-00863-1.

    PMID: 38206518
  21. 21

    Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood.

    Combier A, Frantz C, Wipff J, et al.

    Joint bone spine 2023; (90(2)):105501 doi:10.1016/j.jbspin.2022.105501.

    PMID: 36574572
  22. 22

    Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.

    Ong MS, Ringold S, Kimura Y, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(10)):1910-1920 doi:10.1002/art.41892.

    PMID: 34105303
  23. 23

    Evolution of treatment options for juvenile idiopathic arthritis.

    Ren T, Guan JH, Li Y, et al.

    World journal of orthopedics 2024; (15(9)):831-835 doi:10.5312/wjo.v15.i9.831.

    PMID: 39318493
  24. 24

    [Protocols in pediatric rheumatology (PROKIND): treat-to-target in polyarticular juvenile idiopathic arthritis].

    Horneff G, Minden K, Foell D, et al.

    Zeitschrift fur Rheumatologie 2024; (83(1)):15-27 doi:10.1007/s00393-023-01452-0.

    PMID: 38157052
  25. 25

    Efficacy of biologic DMARDs in improving the clinical response of patients with polyarticular juvenile idiopathic arthritis: a meta-analysis of RCTs.

    de Freitas PHAG, de Almeida MMG, Simão ÁMS, et al.

    Advances in rheumatology (London, England) 2025; (65(1)):55 doi:10.1186/s42358-025-00488-x.

    PMID: 41214794

This page is for informational purposes only and does not replace professional medical advice. Always discuss medication risks and benefits with your pediatric rheumatologist.

Get notified when new evidence is published on Juvenile idiopathic arthritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.